A new test co-developed by a Boston University School of Medicine (BUSM) researcher will allow patients suspected of having lung cancer to be subjected to fewer and less-invasive tests to determine if they have the disease. The team state that there is an increase in the number of lesions suspicious for lung cancer found on chest imaging of current and former smokers. In the past, these patients have been subjected to invasive tests when traditional bronchoscopy tests prove inconclusive. Now, the new genomic-based test provide physicians and patients with an additional piece of scientifically reliable information to consider when determining their next diagnostic step. The opensource study is published in the New England Journal of Medicine.
The current study found that a genomic biomarker can accurately determine the likelihood of a lung lesion being malignant. The data findings were validated from two large, prospective, multicenter studies called Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer (AEGIS) I and II. The researchers state that the findings will allow physicians to confidently identify patients who are at low probability for having lung cancer thus sparing them from costly and risky procedures.
Previous studies from the team found that the pattern of gene activity in cells lining the upper respiratory tract can identify cancer that is developing deeper in the lung. The ability to test for molecular changes in this ‘field of injury’ allows the medical team to rule out the disease earlier without invasive procedures. Conceptually, they add, this may have significant implications for other diseases.
The current study involved 639 patients (298 in AEGIS I and 341 in AEGIS II) at 28 sites in the United States, Canada and Ireland who were undergoing bronchoscopy, a common nonsurgical procedure to assess lung lesions for cancer. Using airways cells collected by the bronchoscopy, the researchers found this genomic test, when evaluated with the bronchoscopy, had a combined sensitivity of 97 percent for detecting lung cancer, compared to 75 percent for bronchoscopy alone.
The team states that the current study validates the effectiveness of the bronchial genomic biomarker among those undergoing bronchoscopy in two independent groups. The results showed that the genomic-based test has high sensitivity across different sizes, locations, stages and cell types of lung cancer. The statistical analysis showed that a combination of the biomarker and bronchoscopy has a sensitivity of 96 percent and 98 percent in the AEGIS-1 and AEGIS-2 groups.
An estimated 250,000 patients undergo a bronchoscopy for suspected lung cancer each year with approximately 40 percent producing non-diagnostic results, the researchers state. They go on to add that this can lead to invasive procedures such as transthoracic needle biopsy or surgical lung biopsy that are risky and expensive.
The team surmise that in intermediate risk patients with a non-diagnostic bronchoscopy, a negative genomic test warrants consideration of a more conservative diagnostic approach that could reduce unnecessary invasive testing in patients without lung cancer. The researchers foresee that this new test will improve the diagnostic work up for lung cancer by reducing patient anxiety, unnecessary procedures and ultimately saving valuable healthcare resources and money.
Michelle is a health industry veteran who taught and worked in the field before training as a science journalist.
Featured by numerous prestigious brands and publishers, she specializes in clinical trial innovation--expertise she gained while working in multiple positions within the private sector, the NHS, and Oxford University.